https://www.astrazeneca.se/ 2026-07-15T11:04:32.694Z https://www.astrazeneca.se/privacy-policy.html 2016-05-15T11:36:51.363Z https://www.astrazeneca.se/sjukdomsomraden.html 2025-10-22T09:10:08.459Z https://www.astrazeneca.se/sjukdomsomraden/onkologi.html 2025-09-10T10:12:09.552Z https://www.astrazeneca.se/sjukdomsomraden/hjart-karl-njurar-och-amnesomsattning.html 2025-09-10T10:14:40.667Z https://www.astrazeneca.se/sjukdomsomraden/luftvagar-och-immunologi.html 2025-10-09T06:10:42.192Z https://www.astrazeneca.se/sjukdomsomraden/vacciner-och-immunterapier.html 2025-09-10T10:15:49.845Z https://www.astrazeneca.se/sjukdomsomraden/sallsynta-sjukdomar.html 2025-09-10T10:16:19.477Z https://www.astrazeneca.se/om-oss.html 2026-03-04T10:41:11Z https://www.astrazeneca.se/om-oss/ledningsgrupp-sverige.html 2026-07-26T10:07:51.251Z https://www.astrazeneca.se/om-oss/korta-fakta.html 2026-03-04T10:33:37Z https://www.astrazeneca.se/om-oss/verksamheten-i-sverige.html 2026-03-04T10:17:19Z https://www.astrazeneca.se/om-oss/verksamheten-i-sverige/goteborg.html 2026-02-26T14:46:30.050Z https://www.astrazeneca.se/om-oss/verksamheten-i-sverige/goteborg/relocate-to-gothenburg.html 2025-01-16T09:01:16.224Z https://www.astrazeneca.se/om-oss/verksamheten-i-sverige/Sodertalje.html 2026-03-04T10:04:32Z https://www.astrazeneca.se/om-oss/verksamheten-i-sverige/Sodertalje/sweden-biologics-center-.html 2025-11-27T12:11:33.249Z https://www.astrazeneca.se/om-oss/verksamheten-i-sverige/stockholm.html 2025-03-04T13:09:21.857Z https://www.astrazeneca.se/om-oss/mentorskapsprogrammet-exchange.html 2025-10-10T11:40:58.115Z https://www.astrazeneca.se/om-oss/mentorskapsprogrammet-exchange/astrazeneca-exchange-nordics.html 2025-10-10T09:30:20.412Z https://www.astrazeneca.se/om-oss/mentorskapsprogrammet-exchange/var-vision-astrazeneca-exchange-nordics.html 2025-10-10T11:45:27.058Z https://www.astrazeneca.se/om-oss/mentorskapsprogrammet-exchange/hur-det-fungerar-astrazeneca-exchange.html 2025-10-10T09:05:17.515Z https://www.astrazeneca.se/om-oss/mentorskapsprogrammet-exchange/vara-mentorer-astrazeneca-exchange.html 2025-10-10T07:02:25.987Z https://www.astrazeneca.se/om-oss/mentorskapsprogrammet-exchange/vart-team-astrazeneca-exchange.html 2025-10-10T09:33:42.221Z https://www.astrazeneca.se/om-oss/innovation-i-partnerskap.html 2025-05-08T11:32:41.446Z https://www.astrazeneca.se/karriar.html 2026-03-04T10:44:15Z https://www.astrazeneca.se/karriar/medarbetare-beraettar.html 2024-02-14T14:17:07.342Z https://www.astrazeneca.se/karriar/Mitt-ledarskap-Elisabeth-Bjork.html 2023-11-01T14:22:12.042Z https://www.astrazeneca.se/karriar/early-talent-careers.html 2026-01-15T12:33:46.949Z https://www.astrazeneca.se/karriar/early-talent-careers-sv.html 2026-01-15T12:30:34.062Z https://www.astrazeneca.se/hallbar-verksamhet.html 2026-05-11T12:33:32.322Z https://www.astrazeneca.se/hallbar-verksamhet/hallbar-verksamhet.html 2025-10-06T12:13:37.024Z https://www.astrazeneca.se/hallbar-verksamhet/hallbar-verksamhet/healthy-heart-africa.html 2025-01-31T11:10:28.073Z https://www.astrazeneca.se/hallbar-verksamhet/hallbar-verksamhet/young-health-programme.html 2025-10-06T11:39:09.619Z https://www.astrazeneca.se/hallbar-verksamhet/klimat-och-natur.html 2025-10-06T12:26:09.498Z https://www.astrazeneca.se/hallbar-verksamhet/klimat-och-natur/minskad-klimatpaverkan.html 2025-11-05T08:42:15.236Z https://www.astrazeneca.se/hallbar-verksamhet/klimat-och-natur/miljo-och-hallbarhetsrapporter.html 2025-10-22T11:26:34.779Z https://www.astrazeneca.se/hallbar-verksamhet/klimat-och-natur/ambition-zero-carbon.html 2026-05-11T13:41:00.394Z https://www.astrazeneca.se/hallbar-verksamhet/jamlik-halsa.html 2025-10-06T12:17:39.017Z https://www.astrazeneca.se/hallbar-verksamhet/motstandskraftiga-sjukvardssystem.html 2025-10-06T12:19:11.005Z https://www.astrazeneca.se/hallbar-verksamhet/Vart-satt-att-arbeta.html 2025-11-05T08:37:59.161Z https://www.astrazeneca.se/hallbar-verksamhet/Vart-satt-att-arbeta/samhallstod.html 2025-10-06T12:00:04.589Z https://www.astrazeneca.se/hallbar-verksamhet/Vart-satt-att-arbeta/samhallstod/grymt-fett.html 2025-10-01T10:01:12.356Z https://www.astrazeneca.se/hallbar-verksamhet/Vart-satt-att-arbeta/oppen-redovisning-av-vardeoverforingar.html 2026-05-27T14:10:27.517Z https://www.astrazeneca.se/aktieagare.html 2026-07-27T06:15:03.468Z https://www.astrazeneca.se/aktieagare/utdelning.html 2024-03-05T14:42:24.225Z https://www.astrazeneca.se/aktieagare/ekonomiska-rapporter.html 2026-07-27T05:42:06.007Z https://www.astrazeneca.se/search-results.html 2017-01-19T16:45:00.152Z https://www.astrazeneca.se/500.html 2016-05-15T12:23:54.240Z https://www.astrazeneca.se/503.html 2016-06-20T13:44:19.524Z https://www.astrazeneca.se/404.html 2024-06-25T04:30:32.524Z https://www.astrazeneca.se/media.html 2026-02-14T07:42:45.026Z https://www.astrazeneca.se/media/pressmeddelanden.html 2024-03-12T04:45:32.756Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden.html 2017-02-16T08:34:49.052Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017.html 2017-02-16T08:34:49.052Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-expands-1st-line-lung-cancer-immuno-oncology-program.html 2017-02-21T15:53:00.720Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/symbicort-granted-paediatric-exclusivity-in-the-us.html 2017-02-13T15:48:32.175Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-plc-s-resultatrapport-foer-helaret-och-fjaerde-kvart.html 2017-02-13T15:53:08.332Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-leder-nytt-industriforskningscentrum-foer-utveckling.html 2017-02-13T15:56:17.304Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/siliq--brodalumab--approved-by-the-us-fda-for-adult-patients-wit.html 2017-02-16T11:52:23.257Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/lynparza-meets-primary-endpoint-in-phase-iii-trial-in-brca-mutat.html 2017-02-17T06:41:20.478Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/updated-durvalumab-monotherapy-data-confirm-results-in-urothelia.html 2017-02-18T08:33:31.293Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-enters-agreement-with-tersera-therapeutics-for-zolad.html 2017-02-20T07:25:07.636Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/zs-9--sodium-zirconium-cyclosilicate--receives-positive-chmp-opi.html 2017-02-24T13:29:21.749Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/fda-approves-once-daily-qtern--dapagliflozin-and-saxagliptin--ta.html 2017-02-28T06:28:29.453Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/medimmune-and-sanofi-pasteur-form-alliance-to-develop-and-commer.html 2017-03-03T06:54:06.479Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/fas-iii-studien-solo-2-visar-pa-foerlaengd-progressionsfri-oever.html 2017-03-14T18:44:38.008Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-receives-complete-response-letter--from-us-fda-for-z.html 2017-03-17T07:17:02.948Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-and-circassia-enter-strategic-collaboration-in-respi.html 2017-03-17T07:22:27.688Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca_s-cvd-real-study-shows-sglt-2-inhibitors-significant.html 2017-03-20T16:30:48.400Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/tagrisso-approved-in-china-as-first-in-class-treatment-for-egfr-.html 2017-03-27T05:36:57.300Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-to-share-its-robust-early-science-in-oncology-with-t.html 2017-03-28T09:18:17.046Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca_s-potential-medicine-for-neuromyelitis-optica-spectr.html 2017-03-29T05:46:15.767Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/tagrisso--osimertinib--receives-us-fda-full-approval.html 2017-03-31T04:56:01.944Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/tagrisso-receives-full-approval-in-the-eu.html 2017-04-25T14:24:50.783Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-plc-s-resultatrapport-foer-foersta-kvartalet-2017.html 2017-04-27T06:14:32.535Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca_s-imfinzi--durvalumab--receives-us-fda-accelerated-a.html 2017-05-01T18:32:24.398Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/lungcancerstipendium-till-dr-mikael-johansson-.html 2017-05-08T11:48:05.770Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-provides-update-on-stratos-1-phase-iii-trial-of-tral.html 2017-05-10T05:53:35.375Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/imfinzi-significantly-reduces-the-risk-of-disease-worsening-or-d.html 2017-05-12T06:18:18.911Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/stipendium-till-katalin-dobra-.html 2017-05-12T09:54:06.760Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-to-present-scientific-advancements-from-growing-resp.html 2017-05-18T06:15:41.292Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/losningar-for-mer-jamlik-tillgang-till-cancerlakemedel.html 2017-05-18T13:10:52.759Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/brodalumab-receives-positive-chmp-opinion-for--the-treatment-of-.html 2017-05-19T14:43:31.911Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-enters-agreement-with-recordati-for-seloken-in-europ.html 2017-05-22T05:24:01.741Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/phase-iii-zonda-trial-for-benralizumab-shows-ability-to-reduce-o.html 2017-05-22T18:38:32.468Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/bydureon-exscel-trial-meets-primary-safety-objective-in-type-2-d.html 2017-05-23T06:19:48.972Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-delivers-new-data-on-expanding-portfolio-of-cancer-m.html 2017-05-26T06:22:01.488Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/lynparza-significantly-reduces-the-risk-of-disease-worsening-or-.html 2022-02-16T08:37:22.963Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-enters-agreement-with-gruenenthal-to-divest-rights-t.html 2017-06-07T07:34:32.922Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-to-present-scientific-advances-in-cardiovascular-and.html 2017-06-08T05:40:35.585Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-presents-new-data-underpinning-safety-profile-and-re.html 2017-06-12T06:16:33.204Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/nordisk-registerstudie-pa-ada--behandling-av-typ-2-diabetes-med-0.html 2017-06-12T17:33:13.408Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/upptaeckter-som-raeddar-liv--arets-tema-foer-sommarforskarskolan.html 2017-06-13T06:08:19.560Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/faslodex--fulvestrant--receives-positive-chmp-opinion-for-use-in.html 2017-06-26T06:08:47.996Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/kyntheum-approved-in-the-eu-for-the-treatment-of-adults-with-mod.html 2017-07-20T09:56:09.046Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/upptaeckter-som-raeddar-liv--arets-tema-foer-sommarforskarskolan0.html 2017-07-26T09:06:12.550Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/faslodex-receives-eu-approval-as-first-line-therapy-for-advanced.html 2017-07-26T16:01:42.786Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-and-merck-establish-strategic-oncology-collaboration.html 2017-07-27T05:10:49.901Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-reports-initial-results-from-the-ongoing-mystic-tria.html 2017-07-27T05:14:38.472Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/tagrisso-significantly-improves-progression-free-survival-in-the.html 2017-07-27T05:17:31.068Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-plc-s-resultatrapport-foer-foersta-halvaret-och-andr.html 2017-07-27T05:32:51.111Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/imfinzi-granted-breakthrough-therapy-designation-by-us-fda-for-p.html 2017-07-31T08:27:25.195Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/acalabrutinib-granted-breakthrough-therapy-designation-by-us-fda.html 2017-08-01T09:09:35.871Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/us-fda-accepts-regulatory-submission-for-acalabrutinib-and-grant.html 2017-08-02T09:21:13.466Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/registerdata-visar--sglt-2-haemmare--jaemfoert-med-andra-glukoss.html 2017-08-16T09:02:40.535Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/lynparza-receives-additional-and-broad-approval-in-the-us-for-ov.html 2017-08-17T19:37:43.545Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/extended-treatment-with-brilinta-reduces-risk-of-cardiovascular-.html 2017-08-24T06:11:30.194Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/faslodex-receives-us-fda-approval-as-monotherapy-for-expanded-us.html 2017-08-28T06:18:56.280Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-and-takeda-establish-collaboration--to-develop-and-c.html 2017-08-29T06:41:38.761Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-highlights-latest-advances-in-lung-cancer-at-the-esm.html 2017-08-31T06:24:42.395Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-to-present-data-on-next-generation-of-biologics-at-e.html 2017-09-04T06:03:45.328Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/tezepelumab-significantly-reduced-asthma-exacerbations-for-a-bro.html 2017-09-06T21:14:03.580Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/duaklir-significantly-improves-lung-function-in-copd-patients.html 2017-09-07T06:15:23.441Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/celgene-and-astrazeneca-provide-update-on-the-fusion-clinical-tr.html 2017-09-07T12:12:44.664Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/foerpackning-maerkt-selokenzoc-100-mg-kan-innehalla-fel-burk.html 2017-09-08T10:41:43.133Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-presents-superior-progression-free-survival-for-imfi.html 2017-09-09T11:59:56.317Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-s-tagrisso-shows-potential-as-a-new-standard-of-care.html 2017-09-09T12:00:44.705Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-presents-new-results-identifying-severe-asthma-patie.html 2017-09-11T09:07:33.894Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-and-aspen-enter-agreement-for-remaining-rights-to-an.html 2017-09-14T06:04:56.796Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/bydureon-exscel-trial-demonstrates-favourable-cardiovascular--cv.html 2017-09-14T15:35:03.837Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/bevespi-aerosphere-demonstrates-statistically-significant-improv.html 2017-09-25T05:27:33.917Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/tagrisso-ingar-i-laekemedelsfoermanerna.html 2017-10-03T14:19:26.935Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/tagrisso-granted-breakthrough-therapy-designation-by-us-fda-for-.html 2017-10-09T06:12:35.136Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/the-european-medicines-agency-accepts-marketing-authorisation-ap.html 2017-10-09T06:15:10.541Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-shares-its-comprehensive-scientific-approach-at-the-.html 2017-10-16T06:07:05.525Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/us-fda-accepts-supplemental-biologics-license-application-for-im.html 2017-10-17T06:13:34.103Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/us-fda-accepts-regulatory-submission-for--lynparza-in-metastatic.html 2017-10-18T06:01:46.352Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/us-fda-approves-new-easy-to-use--once-weekly-bydureon-bcise-inje.html 2017-10-23T06:23:20.110Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-and-msd-rapidly-advance-lynparza-in-japan-with-a-sec.html 2017-10-23T06:26:23.227Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-and-incyte-enter-clinical-trial-collaboration-in-ear.html 2017-10-31T06:43:17.229Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/fda-godkaenner-astrazenecas-calquence--acalabrutinib--foer-vuxna.html 2017-10-31T17:35:14.182Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-provides-update-on-tralokinumab-phase-iii-programme-.html 2017-11-01T07:14:57.662Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-shares-scientific-updates-from-its-extensive-cardiov.html 2017-11-08T06:18:27.496Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-plc-s-resultatrapport-foer-foersta-nio-manader-och-t.html 2017-11-09T07:25:08.210Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/benralizumab-far-positivt-chmp-utlatande-i-eu--foer-behandling-a.html 2017-11-10T12:20:59.811Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/fasenra--benralizumab--receives-us-fda-approval-for-severe-eosin.html 2017-11-15T07:19:11.148Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/faslodex-receives-us-fda-approval-for-the-treatment-of-advanced-.html 2017-11-15T07:22:06.395Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-makes-regulatory-submission-for-tagrisso-in-1st-line.html 2017-11-27T06:30:45.289Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-and-chinese-future-industry-investment-fund-establis.html 2017-11-27T07:19:54.522Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/the-european-medicines-agency-accepts-regulatory-submission-for-.html 2017-11-28T06:43:29.076Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/tudorza-reduces-exacerbations-and-demonstrates-cardiovascular-sa.html 2017-12-04T06:29:30.826Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/astrazeneca-to-highlight-its-commitment-to-blood-cancers-at-the-.html 2017-12-06T06:20:27.555Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2017/us-fda-accepts-regulatory-submission-for-tagrisso-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-18122017.html 2017-12-18T07:51:49.414Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016.html 2016-05-09T13:02:36.317Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-tecknar-avtal-med-prostrakan-for-ratten-till-moventig-i-europa-01032016.html 2017-02-16T08:35:16.890Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-reports-top-line-result-of-tremelimumab-monotherapy-trial-in-mesothelioma-29022016.html 2017-02-14T16:47:17.702Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-enters-licensing-agreement-with-china-medical-system-holdings-for-hypertension-medicine-29022016.html 2017-02-09T13:26:28.877Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/acalabrutinib-recommended-for-orphan-drug-designation-in-europe-for-three-indications-25022016.html 2017-02-14T17:00:29.292Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/brilique-ticagrelor-har-godkants-i-EUfor-utvidgad-behandling-av-patienter-med-tidigare-hjartinfarkt-19022016.html 2017-02-14T16:49:49.417Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/Zurampic-lesinurad-approved-in-the-European-Union-for-patients-with-gout-19022016.html 2017-02-09T13:39:29.975Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/Durvalumab-granted-Breakthrough-Therapy-Designation-by-US-FDA-for-treatment-of-patients-with-PD-L1-positive-urothelial-bladder-cancer-17022016.html 2017-02-09T13:40:26.117Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazenecas-bioventurehub-expanding-with-leading-science-11022016.html 2017-02-09T13:41:29.125Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-PLCs-resultatrapport-for-helaret-och-fjarde-kvartalet-2015-04022016.html 2017-02-09T13:42:23.183Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/TAGRISSO-har-godkants-i-EU-som-den-forsta-behandlingen-for-patienter-med-EGFR-T790M-mutationspositiv-metastaserad-icke-smacellig-lungcancer03022016.html 2017-02-09T13:43:11.486Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/Tagrisso_osimertinib_approved_in_EU03022016.html 2017-02-09T13:44:14.232Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/Lynparza-olaparib-granted-breakthrough-therapy28012016.html 2017-02-09T13:45:17.345Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-and-moderna-therapeutics-announce-new11012016.html 2017-02-09T13:46:39.692Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/medimmune-receives-fast-track-designation-in-the-us-for-medi8852.html 2017-02-14T16:58:04.881Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca_s-potential-medicine-for-neuromyelitis-optica-receiv.html 2017-02-09T14:18:54.067Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-reports-top-line-results-from-the-brilinta-socrates-.html 2020-01-06T08:05:15.982Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/tagrisso_--osimertinib--approved-in-japan-for-patients-with-egfr.html 2017-02-09T14:20:13.080Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/brilinta-preferred-over-clopidogrel-in-updated-american-college-.html 2017-02-09T14:21:12.747Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/pandemic-influenza-vaccine-receives-positive--chmp-opinion.html 2017-02-09T14:21:48.734Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-to-showcase-clinical-and-scientific-leadership-in-lu.html 2017-02-09T14:22:24.133Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-and-eli-lilly-and-company-announce-continuation-of-p.html 2017-02-09T14:23:28.275Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-showcases-breadth-of-oncology-portfolio-at-aacr-2016.html 2017-02-09T14:24:13.151Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-lanserar-integrerat-forskningsinitiativ-inom-genomik.html 2017-02-09T14:25:09.011Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/bevespi-aerosphere-har-godkaents-av-fda-foer-patienter-med-kol.html 2017-02-09T14:25:46.435Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-enters-into-us-licensing-agreement-with-ironwood-pha.html 2017-02-09T14:26:29.553Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-plc_s-resultatrapport-foer-foersta-kvartalet-2016.html 2017-02-09T14:27:32.688Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/positive-chmp-opinion-for-caz-avi-in-the-eu-for-serious-bacteria.html 2017-02-14T16:48:54.503Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/selumetinib-granted-orphan-drug-designation-in-the-us-for-adjuva.html 2017-02-09T14:28:53.609Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-to-highlight-the-breadth-of--its-respiratory-medicin.html 2017-02-09T14:29:37.242Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-tillkaennager-positiva-resultat-fran-fas-iii-studier.html 2017-02-09T14:30:20.777Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-provides-top-line-results-from-lynparza-gold-trial-i.html 2017-02-09T10:08:05.990Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-highlights-continued-progress-of-oncology-pipeline-a.html 2017-02-09T10:07:32.060Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/studie-visar-att-mobil-app-foerbaettrade-foeljsamhet-till-behand.html 2017-02-09T10:06:56.241Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-receives-complete-response-letter-from-us-fda-for-so.html 2017-02-09T10:06:20.957Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca_s-faslodex-met-primary-endpoint-in-first-line-treatm.html 2022-02-16T08:39:57.366Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/positive-chmp-opinion-in-eu-for-saxa-dapa--saxagliptin-and-dapag.html 2016-06-20T13:53:15.619Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-licenses-zurampic-to-gruenenthal-gmbh-in-europe-and-.html 2016-06-20T13:58:26.104Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/tagrisso--osimertinib--shows-clinical-activity-in-patients-with-.html 2016-06-20T14:22:26.569Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/lynparza--olaparib---latest-data-suggest-potential-overall-survi.html 2016-06-20T14:29:22.873Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-ingar-kommersialiseringsavtal-med-aspen-foer-produkt.html 2016-06-20T14:51:55.417Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/christer-betsholtz-appointed-new-head-of-karolinska-institutet-a.html 2017-02-09T09:56:08.342Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-provides-update-on-flumist-quadrivalent-vaccine-in-t0.html 2017-02-09T14:56:38.952Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/new-antibiotic-zavicefta-approved-in-the-european-union-for-pati.html 2017-02-09T15:08:36.012Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-enters-licensing-agreements-with-leo-pharma-in-skin-.html 2017-02-09T15:15:19.428Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/tagrisso-met-primary-endpoint-in-phase-iii-2nd-line-lung-cancer-.html 2017-02-09T15:21:29.146Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-receives-approval-in-the-eu-for-qtern--saxagliptin-a.html 2017-02-09T15:26:45.867Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca_s-antibiotic-zavicefta-met-primary-endpoints-in-phas.html 2017-02-09T15:32:51.053Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-plc-s-resultatrapport-foer-foersta-halvaret-och-andr.html 2017-02-09T15:45:39.312Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-provides-update-on-phase-iii-trial-of-selumetinib-in.html 2017-02-09T15:51:55.518Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-announces-investment-in-moderna.html 2017-02-09T15:56:46.798Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/-astrazeneca-and-lilly-receive-fda-fast-track-designation-for-az.html 2017-02-09T16:00:51.778Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-to-sell-small-molecule-antibiotics-business-to-pfize.html 2017-02-09T16:06:55.988Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-to-present-new-data-highlighting-its-growing-respira.html 2017-02-09T16:10:31.980Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/benralizumab-phase-iii-trials-show-positive-results-in-severe-as.html 2017-02-09T16:17:31.508Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-announces-two-new-phase-iiib-trials-for-forxiga-in-c.html 2017-02-09T16:22:06.694Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/foerdubblade-sjukdomskostnader-i-sverige-foer-typ-2-diabetes-und.html 2017-02-09T16:26:16.105Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/stora-skillnader-i-varden-av-typ-2-diabetes-i-danmark--norge-och.html 2017-02-09T16:43:22.704Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/phase-iii-combination-trial-of-bydureon-and-forxiga-shows-signif.html 2017-02-13T13:14:23.541Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/---astrazeneca-provides-update-on-cediranib-eu-marketing-authori.html 2017-02-13T13:21:22.691Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-presents-new-data-on-faslodex-in-breast-cancer-and-p.html 2017-02-13T13:28:31.213Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/medimmune-out-licenses-potential-medicine-for-inflammatory-disea.html 2017-02-13T13:33:05.565Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-reports-top-line-results-from-the-brilinta-euclid-tr.html 2017-02-13T13:36:36.556Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-enters-agreement-with-aralez-for-beta-blocker-medici.html 2017-02-13T13:46:45.564Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-enters-agreement-with-cilag-gmbh-international-to-di.html 2017-02-13T13:51:12.198Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/fda-accepts-for-review-new-drug-application-for-sodium-zirconium.html 2017-02-13T15:02:06.241Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/lynparza-phase-iii-solo-2-trial-shows-significant-progression-fr.html 2017-02-13T15:06:02.715Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-plc-s-resultatrapport-foer-de-foersta-nio-manaderna-.html 2017-02-13T15:16:20.110Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-uppmaerksammar-vaerldsdiabetesdagen-den-14-november.html 2017-02-13T15:24:48.138Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-head-and-neck-cancer-trials-resume-new-patient-enrol.html 2017-02-13T15:29:56.494Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/astrazeneca-takes-latest-scientific-advances-in-oncology-to-majo.html 2017-02-13T15:33:14.821Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/tagrisso--osimertinib--visar-pa-foerbaettrade-resultat-vid-egfr-.html 2017-02-13T15:36:48.740Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2016/us-fda-accepts-first-biologics-license-application-for-astrazene.html 2017-02-13T15:39:55.409Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015.html 2016-05-09T13:03:55.043Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/zurampic-lesinurad-approved-by-us-fda-23122015.html 2017-02-16T12:37:34.480Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/iressa-approved-by-us-fda-for-firstline-treatment-14062015.html 2017-02-16T12:38:16.175Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-and-tillotts-pharma-09072015.html 2017-02-16T12:38:59.716Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/tagrisso-osimertinib--lesinurad-brilique-18122015.html 2017-02-16T12:40:00.919Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-to-collaborate-with-the-University-of-Michigan-17062015.html 2017-02-16T12:40:49.577Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/durvalumab-atlantic-trial-supports-18122015.html 2017-02-16T12:41:52.983Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-to-collaborate-with-inserm-17062015.html 2017-02-16T12:42:26.391Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-appoints-pam-cheng-16062015.html 2017-02-16T12:43:14.434Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/tillverkar-nedbrytbar-plast-och-renar-vatten-15062015.html 2017-02-16T12:43:53.405Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-enhances-long-term-growth-through-oncology-17122015.html 2017-02-16T12:44:39.079Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/new-realworld-analysis-finds-08062015.html 2017-02-16T12:45:16.543Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-to-strengthen-therapy-area-franchise-16122015.html 2017-02-16T12:45:58.855Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-presents-new-positve-phase-iii-data-06062015.html 2017-02-16T12:47:01.052Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-continues-strategic-investment-in-china-16122015.html 2017-02-16T12:47:32.800Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-to-present-data-demonstrating-progress-03062015.html 2017-02-16T12:48:18.507Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/discussions-with-acerta-pharma-bv-14122015.html 2017-02-16T12:48:46.283Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-i-samarbete-med-nytt-11122015.html 2017-02-16T12:49:32.874Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-updates-on-immunooncology-02062015.html 2017-02-16T12:50:10.467Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-provides-update-on-brodalumab-22052015.html 2017-02-16T12:50:41.383Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-enters-into-agreement-with-perrigo-23112015.html 2017-02-16T12:51:12.277Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-investerar-i-ny-18052015.html 2017-02-16T12:51:46.940Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-expands-technological-investment-20112015.html 2017-02-16T12:52:33.087Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-to-update-on-progress-13052015.html 2017-02-16T12:53:04.247Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-and-montreal-heart-institute-to-screen-80000-sample-13052015.html 2017-02-16T12:53:57.058Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/svenska-lungcancerstudiegruppen-slusg-08052015.html 2017-02-16T12:54:27.981Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/us-fda-grants-priority-review-for-potential-29042015.html 2017-02-16T12:55:01.793Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/positive-phase-iii-results-for-two-antibiotics-27042015.html 2017-02-16T12:55:55.410Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-and-sanofi-exchange-20112015.html 2017-02-16T12:56:23.793Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/delrsrapport-kvartal-24042015.html 2017-02-16T12:56:50.591Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-enters-strategic-immunooncology-24042015.html 2017-02-16T12:57:22.802Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/tagrisso-azd9291-approved-by-the-us-fda-13112015.html 2017-02-16T12:58:00.882Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-and-innate-pharma-24042015.html 2017-02-16T12:58:40.174Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/insatser-fr-svensk-kardiolgi-uppmrksammas-23042015.html 2017-02-16T12:59:21.630Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/outtrttlig-brstcancerkmpe-fr-prestigetyngd-13112015.html 2017-02-16T12:59:50.627Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-and-bina-collaborate-21042015.html 2017-02-16T13:00:52.798Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-tillknnager-uppdaterade-data-17042015.html 2017-02-16T13:01:34.182Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/selumetinib-granted-orphan-drug-17042015.html 2017-02-16T13:02:46.779Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/medimmune-and-immunocore-announce-16042015.html 2017-02-16T13:03:29.344Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/tremelimumab-har-beviljats-srlkemedelsstatus-15042015.html 2017-02-16T13:04:00.937Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/fda-advisory-committee-reviews-14042015.html 2017-02-16T13:05:07.770Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-to-showcase-strong-13042015.html 2017-02-16T13:05:50.753Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-presents-positive-new-data-anifrolumab-10112015.html 2017-02-16T13:06:49.871Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/nytt-behandlingsalternativ--fr-frstoppning-01042015.html 2017-02-16T13:07:23.687Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-strengthens-cardiovascular-and-metabolic-06112015.html 2017-02-16T13:08:06.512Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-to-collaborate-with-the-harvard-stem-cell-institute-25032015.html 2017-02-16T13:08:51.853Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-och-daiichi-sankyo-19032015.html 2017-02-16T13:09:38.753Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/delrsrapport-astrazeneca-plc-05112015.html 2017-02-16T13:10:19.472Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-announces-positive-phase-iii-top-18032015.html 2017-02-16T13:11:21.101Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/pegasustimi-54-studien-visar-att-lngtidsbehandling-14032015.html 2017-02-16T13:14:40.929Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-refines-its-financial-reporting-06032015.html 2017-02-16T13:15:21.412Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-to-participate-in-us-fda-04032015.html 2017-02-16T13:16:33.745Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/20150303-astrazeneca-completes-acquisition-of-rights-03032015.html 2017-02-16T13:21:59.689Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/fda-advisory-committee-recommends-the-approval-23102015.html 2017-02-16T13:22:35.151Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-announces-nonexecutive-board-changes-17022015.html 2017-02-16T13:23:12.280Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/us-district-court-decision-in--pulmicort-respules-16022015.html 2017-02-16T13:23:48.071Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-and-lilly-expand-immunooncology-research-22102015.html 2017-02-16T13:25:41.508Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-to-acquire-rights-to-actavis-branded-05022015.html 2017-02-16T13:26:29.981Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/sammanfattning-av-delrsrapport-fr-fjrd-05022015.html 2017-02-16T13:27:06.660Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-opens-new-manufacturing-20102015.html 2017-02-16T13:27:40.476Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-anvndning-av-crisprteknolog-29012015.html 2017-02-16T13:28:15.201Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/losec-nu-tillgngligt-i-matbutiker-16102015.html 2017-02-16T13:28:48.057Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-receives-complete-response-letter-16102015.html 2017-02-16T13:29:18.948Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/marketing-authorisation-application-for-gout-22012015.html 2017-02-16T13:30:01.058Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/studien-pegasustimi-54-fr-brilinta-14012015.html 2017-02-16T13:30:37.794Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/medimmune-enters-licensing-agreement-with-omnis-12012015.html 2017-02-16T13:31:16.338Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/grymt-fett--astrazenecas-filmserie-05102015.html 2017-02-16T13:31:55.123Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/new-england-journal-of-medicine-publishes-results-01102015.html 2017-02-16T13:32:43.809Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/moventig-in-i-hgkostnadsskyddet-28092015.html 2017-02-16T13:33:47.766Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-presents-advances-in-oncology-research-24092015.html 2017-02-16T13:42:17.087Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-to-present-data-demonstrating-diversity-of-22092015.html 2017-02-16T13:43:04.530Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/ny-studie-visar-verlevnadsfrdel-fr-faslodex-16092015.html 2017-02-16T13:43:43.882Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-to-present-comprehensive-diabetes-data-11092015.html 2017-02-16T13:44:19.453Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-purchases-us-biologics-manufacturing-faci-11092015.html 2017-02-16T13:45:13.881Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/unikt-samarbete-mellan-industri-och-akademi-09092015.html 2017-02-16T13:45:56.031Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-to-update-on-leading-lung-cancer-portfolio-04092015.html 2017-02-16T13:46:35.608Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/us-fda-approves-expanded-indication-for-brilinta-03092015.html 2017-02-16T13:47:55.434Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/positive-phase-III-results-demonstrate-efficacy-of-antibiotic-medicine-CAZ-AVI-in-complicated-urinary-tract-infections-02092015.html 2017-02-16T13:48:35.032Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/ny-studie-visar-p-frbttrad-fljsamhet-till-behandling-efter-hjartinfarkt-02092015.html 2017-02-16T13:49:14.678Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-enters-license-agreement-with-daiichi-sankyo-02092015.html 2017-02-16T13:49:57.647Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/ticagrelor-brilique-i-samband-med-kranskrlskirurgi-01092015.html 2017-02-16T13:50:41.103Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-och-valeant-i-samarbete-om-brodalumab-01092015.html 2017-02-16T13:51:26.672Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/subgruppsanalys-frn-pegasustimi-54studien-visar-31082015.html 2017-02-16T13:52:03.243Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-to-present-further-research-into-long-term-prevention-of-cardiovascular-events-for-patients-with-a-history-of-heart-attack-at-ESC-Congress-29082015.html 2017-02-16T13:52:59.385Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-and-peregrine-pharmaceuticals-24082015.html 2017-02-16T13:53:45.815Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-appoints-dr-sean-bohen-evp-24082015.html 2017-02-16T13:54:24.600Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/medimmune-enters-into-strategic-cancer-vaccine-10082015.html 2017-02-16T13:56:24.986Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-and-heptares-therapeutics-enter-agreement-06082015.html 2017-02-16T13:55:41.083Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/medimmune-and-mirati-therapeutics-partner-on-05082015.html 2017-02-16T13:57:03.452Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-and-isis-pharmaceuticals-to-discover-03082015.html 2017-02-16T13:58:14.389Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/resultat-astrazeneca-plc-frsta-halvret-30072015.html 2017-02-16T13:58:47.139Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-agreement-with-genzyme-for-caprelsa-27072015.html 2017-02-16T13:59:26.997Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-provides-update-on-selumetinib-22072015.html 2017-02-16T14:00:41.264Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-completes-agreement-with-tillotts-pharma-17072015.html 2017-02-16T14:01:43.245Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2015/astrazeneca-enters-option-agreement-with-kyowa-hakko-16072015.html 2017-02-16T14:02:41.983Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014.html 2016-05-09T13:05:36.364Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Lynparza-har-godkants-av-amerikanska-19122014.html 2016-05-18T11:18:06.618Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/vrldsdiabetesdagen-14112014.html 2016-05-18T11:17:25.287Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/amgen-and-astrazeneca-announce-positive-11112014.html 2016-05-18T11:16:51.611Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Lynparza-godkand-inom-EU-som-18122014.html 2016-05-18T11:15:58.608Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Moventig-approved-in-the-European-9122014.html 2016-05-18T11:15:23.855Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-to-present-new-data-from-its-growing-11112014.html 2016-05-18T11:14:32.287Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Jury-verdict-favours-AstraZeneca-05122014.html 2016-05-18T11:13:31.924Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-to-divest-myalept-to-aegerion-06112014.html 2016-05-18T11:12:47.258Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/delrsrapport-kvartal-3-och-nio-mnader-06112014.html 2016-05-18T11:12:10.700Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Drug-Application-for-IRESSA-02122014.html 2016-05-18T11:11:39.841Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/medimmune-strengthens-immunooncology-04112014.html 2016-05-18T11:11:05.277Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-pharmacyclics-and-janssen-partner-on-04112016.html 2016-05-18T11:10:19.993Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-and-Eli-Lilly-and-Company-initiate-01122014.html 2016-05-18T11:09:31.708Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-and-pharmacyclics-enter-clinical-04112014.html 2016-05-18T11:08:44.402Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Medimmune-completes-acquisition-of-Definiens-26112014.html 2016-05-18T11:08:01.965Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-completes-strategic-transaction-03112014.html 2016-05-18T11:07:30.925Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/statement-regarding-pfizer-announcement28042014.html 2016-05-18T11:06:45.991Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Duaklir-Genuair-approved-in-the-European-Union-24112014.html 2016-05-18T11:06:19.141Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/us-fda-approves-oncedaily-xigduo-xr-tablets-30102014.html 2016-05-18T11:05:27.876Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-pa-ratt-spar-att-leverera-halbar-18112014.html 2016-05-18T11:04:46.101Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-lanserar-programmet-healthy-heart-28102014.html 2016-05-18T11:04:07.180Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-announces-positive-results-from-phase-iii13052014.html 2016-05-18T11:03:32.608Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-announces-initiation-of-13112014.html 2016-05-18T11:02:53.925Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/lynparza-olaparib-24102014.html 2016-05-18T11:02:02.763Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/stora-utmaningar-inom-typ-2diabetes-21102014.html 2016-05-18T11:01:20.704Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-strengthens-partnership-16102014.html 2016-05-18T11:00:39.443Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-and-QIAGEN-enter-collaboration-28072014.html 2016-05-18T11:00:04.298Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/hyllad-brstcancerspecialist-fr-prestigefylld-utmrkelse-15102014.html 2016-05-18T10:59:20.007Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Medimmune-and-Advaxis-partner-22072014.html 2016-05-18T10:58:51.179Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/positive-results-from-phase-iib-09102014.html 2016-05-18T10:57:39.370Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-reveals-designs-for-new-global-18072014.html 2016-05-17T14:00:33.821Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-updates-on-progress-27092014.html 2016-05-17T13:59:21.185Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/FDA-advisory-committee-votes-25062014.html 2016-05-17T13:58:34.053Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-announces-medimmunes-mavrilimumab12052014.html 2016-05-17T13:57:21.143Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/moventig-naloxegol-receives-positive-26092014.html 2016-05-17T13:56:01.108Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/iressa-receives-chmp-positive-opinion-26092014.html 2016-05-17T13:55:14.274Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazenecas-bioventurehub-25092014.html 2016-05-17T13:54:26.096Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-to-present-respiratory-data-at-ats-201412052014.html 2016-05-17T13:53:31.774Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Stort-intresse-for-AstraZenecas-Sommarforskarskol-16062014.html 2020-01-06T08:00:54.406Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/amgen-and-astrazeneca-announce-positive-results-from-phase-3-study-of-Brodalumab10052014.html 2016-05-17T13:52:20.145Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/US-FDA-Ad-Com-recommends-no-12062014.html 2016-05-17T13:51:33.150Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/lungcancerstipendium-till-bengt-bergman09052014.html 2016-05-17T13:50:49.770Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-in-licenses-Synairgens-SNG001-as-12062014.html 2016-05-17T13:50:13.507Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/forskningsinsatser-for-svensk-kardiologi-uppmarksammas08052014.html 2016-05-17T13:48:19.967Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Brodalumab-treatment-improved-clinical-12062014.html 2016-05-17T13:49:19.115Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-issues-update-on-strategy-to-deliver-value06052014.html 2016-05-17T13:47:41.451Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-to-present-new-data-from-11062014.html 2016-05-17T13:46:57.506Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/us-fda-approves-epanova-for-the-treatment-of-adults.html 2016-05-17T13:46:09.972Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Ny-omfattande-undersokning-03062014.html 2016-05-17T13:45:18.611Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Sjukskoterskeledda-mottagningar-i-primarvarden-20082014.html 2016-05-17T13:44:33.052Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-board-rejects-pfizer-proposal02052014.html 2016-05-17T13:43:26.581Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/statement-regarding-pfizer-announcement02052014.html 2016-05-17T13:42:37.490Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/statement-regarding-pfizer-announcement280420140.html 2016-05-17T13:41:47.604Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-announces-positive-top-line-19082014.html 2016-05-17T13:41:12.494Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazenecas-finansiella-resultat-for-forsta-kvartalet24042014.html 2016-05-17T13:40:13.583Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Justitiedepartementet-i-USA-lagger-19082014.html 2016-05-17T13:39:29.864Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-advances-tralokinumab-14082014.html 2016-05-17T13:38:40.906Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-har-slutfort-rekrytering-av26032014.html 2016-05-17T13:37:50.818Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-announces-top-lin-results-from-13082014.html 2016-05-17T13:36:49.668Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-completes-purchase-of-sumitomo26032014.html 2016-05-17T13:35:53.531Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Stort-intresse-for-AstraZenecas-04082014.html 2016-05-17T13:35:03.064Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/new-open-innovation-platform-launched-offering-access25032014.html 2016-05-17T13:34:25.210Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZenecas-finansiella-resultat-31072014.html 2016-05-17T13:33:37.594Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-and-Kyowa-Hakko-Kirin-30072014.html 2016-05-17T13:32:55.034Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/forxiga-receives-regulatory-approval-in-japan24032014.html 2016-05-17T13:31:57.979Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/astrazeneca-proposes-appointment-of-ann-cairns20032014.html 2016-05-17T13:31:13.413Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Anmal-Dig-till-arets-upplaga-av-Sommarforskarskolan17032014.html 2016-05-17T13:30:17.267Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-agrees-strategic-transaction-with-30072014.html 2016-05-17T13:28:52.832Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-and-Roche-announce-partnership-28082014.html 2016-05-17T13:27:41.965Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/FDA-godkanner-MOVANTIK-i-tablettform-for-behandling-av-16092014.html 2016-05-17T13:26:37.967Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-and-Lilly-announce-alliance-to-develop-16092014.html 2016-05-17T13:25:45.422Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-to-present-research-10092014.html 2016-05-17T13:24:38.129Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Benralizumab-phase-II-COPD-study-published-08092014.html 2016-05-17T13:23:33.938Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Stefan-Woxstrom-ny-marknadsbolagschef-04092014.html 2016-05-17T13:22:30.937Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Hog-langtidsrisk-efter-02092014.html 2016-05-17T13:21:41.671Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Nya-data-indikerar-BrilintaBrilique-01092014.html 2016-05-17T13:20:54.104Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Hjart-karlsjukdomar-kommer-kosta-28082014.html 2016-05-17T13:20:14.121Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-announces-partnership-with-21082014.html 2016-05-17T13:19:28.591Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-and-Mitsubishi-Tanabe-20082014.html 2016-05-17T13:18:36.742Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZenecas-novel-antibiotic-candidate-03062014.html 2016-05-17T13:17:28.675Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-updates-on-the-rapid-progress-03062014.html 2016-05-17T13:16:22.108Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-welcomes-positive-data-31052014.html 2016-05-17T13:15:38.281Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Statement-regarding-Pfizer-withdrawal-26052014.html 2016-05-17T13:07:36.611Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-initiates-phase-III-26052014.html 2016-05-17T13:06:56.694Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-and-MRC-Laboratory-15052014.html 2016-05-17T13:06:03.700Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Continuing-progress-in-accelerating-late-15052014.html 2016-05-17T13:05:15.750Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/AstraZeneca-to-demonstrate-the-strength-15052014.html 2016-05-17T13:04:21.294Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2014/Medimmune-and-Incyte-announce-collaboration-14052014.html 2016-05-17T13:03:30.641Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013.html 2016-05-09T13:06:23.481Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-to-acquire-bristol-myers-squibb-share-of-global-diabetes-alliance-assets-19122013.html 2016-05-17T12:58:29.486Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-announces-top-line-results-from-phase-III-monotherapy-study-of-lesinurad-in-gout-patients-13122013.html 2016-05-17T12:57:53.556Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/FDAs-radgivande-kommitte-rekommenderar-forskningssubstansen-SGLT2-hammaren-dapagliflozin-for-behandling-av-diabetes-typ-2-hos-vuxna-13122016.html 2016-05-17T12:56:52.771Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/FDAs-radgivande-kommitte-rostar-om-forskningssubstansen-metreleptin-12122013.html 2016-05-17T12:56:17.404Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/eu-kommissionen-godkanner-fluenz-tetra-for-forebyggande-av-sasongsinfluensa-hos-barn-06122013.html 2016-05-17T12:55:19.057Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-meddelar-start-av-tva-ytterligare-globala-studier-av-brilique-ticagrelor-28112013.html 2016-05-17T12:54:31.486Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/xigduo-dapagliflozin-och-metforminhydroklorid-far-positivt-chmp-utlatande-i-eu-for-behandling-av-typ-2-diabetes-22112013.html 2016-05-17T12:53:55.699Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/karolinska-institutet-utser-dr-bo-angelin-till-chef-for-integrerat-center-for-kardiovaskulara-och-metabola-sjukdomar-20112013.html 2016-05-17T12:53:14.180Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/fda-accepterar-registreringsansokan-nda-for-naloxegol-19112013.html 2016-05-17T12:52:26.710Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/marc-dunoyer-utnamns-till-ny-cfo-i-astrazeneca-31102013.html 2016-05-17T12:59:02.234Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/delarsrapport-for-tredje-kvartalet-och-nio-manader-2013-sammanfattning-31102013.html 2016-05-17T12:51:02.107Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/us-appeals-court-issues-decision-in-pulmicort-respules-patent-litigation-30112013.html 2016-05-17T12:50:33.556Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-startar-kliniskt-fas-3-program-for-medimmunes-benralizumab-mot-svar-astma-30102016.html 2016-05-17T12:50:00.233Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-startar-kliniskt-fas-3-program-for-selumetinib-en-behandling-under-utveckling-for-patienter-med-icke-smacellig-lungcancer-22102013.html 2016-05-17T12:49:09.405Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/prestigefylld-utmarkelse-till-rosa-hjalte-i-boras-15102013.html 2016-05-17T12:48:26.902Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-starker-sin-onkologiportfolj-genom-medimmunes-forvarv-av-spirogen-som-okar-mojligheterna-inom-antikroppskonjugat-15102013.html 2016-05-17T12:47:43.014Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-ingar-avtal-med-janssen-i-japan-om-gemensam-marknadsforing-av-innovativ-prostatacancerbehandling-11102013.html 2016-05-17T12:47:03.087Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/europeiska-lakemedelsmyndigheten-accepterar-ansokan-for-marknadsforing-av-olaparib-27092013.html 2016-05-17T12:46:26.167Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/europeiska-lakemedelsmyndigheten-accepterar-ansokan-for-marknadsforing-av-naloxegol-27092013.html 2016-05-17T12:45:16.953Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/positivt-eu-yttrande-for-fluenz-tetra-ett-nasspray-vaccin-aktivt-mot-fyra-influensastammar-20092013.html 2016-05-17T12:44:01.133Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/fda-accepterar-registreringsansokan-nda-for-provning-av-produkten-epanova-som-ar-under-utveckling-for-behandling-av-svar-hypertriglyceridemi-18092013.html 2016-05-17T12:43:25.391Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/jan-olof-acke-ny-vd-for-astrazeneca-i-sverige-13092013.html 2016-05-17T12:59:27.260Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-och-merck-ingar-samarbetsavtal-for-utveckling-av-en-oral-wee1-kinashammare-for-behandling-av-cancer-11092013.html 2016-05-17T12:38:26.935Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-startar-kliniska-fas-3-programmet-for-olaparib-en-behandling-under-utveckling-for-patienter-med-brca-muterad-aggstockscancer-04092013.html 2016-05-17T12:37:32.012Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/onglyza-saxagliptin-uppnar-primart-sakerhetsmatt-visar-ingen-okad-risk-for-kardiovaskular-dod-hjartattack-eller-stroke-i-den-kardiovaskulara-studien-savor-02092013.html 2016-05-17T12:36:45.448Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/medimmune-strengthens-immune-mediated-cancer-therapy-portfolio-with-acquisition-of-amplimmune-26082013.html 2016-05-17T12:35:39.135Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/aven-mattlig-viktokning-okar-dodligheten-hos-diabetespatienter-12082013.html 2016-05-17T12:34:47.875Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/Delarsrapport-for-andra-kvartalet-och-forsta-halvaret-2013-01082013.html 2016-05-17T12:34:12.632Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-och-fibrogen-inleder-samarbete-for-att-utveckla-och-kommersialisera-fg-4592-en-behandling-for-anemi-vid-kronisk-njursjukdom-och-fullt-utvecklad-njursvikt-31072013.html 2016-05-17T12:33:24.235Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/us-fda-acknowledges-receipt-of-resubmission-of-the-new-drug-application-for-investigational-compound-dapagliflozin-for-the-treatment-of-type-2-diabetes-26072013.html 2016-05-17T12:32:20.733Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-och-bristol-myers-squibb-ansoker-pa-nytt-om-godkannande-for-dapagliflozin-for-behandling-av-typ-2-diabetes-i-usa-25072013.html 2016-05-17T12:31:44.054Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-stodjer-10-nya-forskningsprojekt-vid-science-for-life-laboratory-16072013.html 2016-05-17T12:31:08.174Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/simon-lowth-chief-financial-officer-lamnar-astrazeneca-15072013.html 2016-05-17T13:00:03.437Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-collaborates-with-cambridge-medical-research-institutions-to-advance-cancer-research-09072013.html 2016-05-17T12:29:21.459Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/forskningsinstitut-i-toxikologi-blir-verklighet-i-astrazenecas-tidigare-laboratorium-i-gartuna-01072013.html 2016-05-17T12:28:27.430Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-och-karolinska-institutet-sluter-avtal-om-integrerat-center-for-kardiovaskulara-och-metabola-sjukdomar-25062013.html 2016-05-17T12:27:33.491Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/ny-behandling-av-typ-2-diabetes-forsta-insulinoberoende-lakemedlet-vid-diabetes-typ-2-ingar-i-lakemedelsformanen-24062013.html 2016-05-17T12:26:41.684Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-and-bristol-myers-squibb-announce-top-line-results-for-savor-timi-53-cardiovascular-outcomes-trial-of-onglyza-saxagliptin-19062013.html 2016-05-17T12:25:49.391Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-selects-location-for-new-global-rd-centre-and-corporate-headquarters-in-cambridge-uk-18062013.html 2016-05-17T12:24:45.440Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/medimmune-astrazenecas-biologics-arm-and-ngm-biopharmaceuticals-announce-agreement-to-discover-and-develop-therapies-for-diabetes-and-obesity-17062013.html 2016-05-17T12:23:28.246Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/diabetesalliansen-lanserar-minaframsteg-12062013.html 2016-05-17T12:22:28.698Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-frvrvar-pearl-therapeutics-10062013.html 2016-05-17T12:21:39.009Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-meddelar-idag-vergripande-resultat-i-oskira-04062013.html 2016-05-17T12:20:51.634Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-enters-agreement-with-hanmi-pharmaceutical-03062013.html 2016-05-24T10:27:35.474Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/studiepathoskolrelateradlunginflammation-30052013.html 2016-05-17T12:18:42.963Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazenca-frvrvar--omthera-pharmaceuticals-28052013.html 2016-05-17T12:16:12.044Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/us-appeals-court-issues-a-temporary-injunction-25052013.html 2016-05-17T12:14:45.792Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-meddelar-uppdateringar-av-sin-accelererade-16052013.html 2016-05-17T12:13:19.803Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/Seminarierapport-Hur-kan-hjartsjukvarden-16042013.html 2016-05-17T12:12:20.837Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/AstraZeneca-meddelar-idag-overgripande-05042013.html 2016-05-17T11:07:19.351Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/AstraZeneca-and-BIND-Therapeutics-announce-22042013.html 2016-05-17T11:04:13.289Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/AstraZenecas-Bokslutsrapport-25042013.html 2016-05-17T11:03:14.497Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/efficacy-of-iressa-confirmed-in-caucasians-13052013.html 2016-05-17T11:02:27.251Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/insatser-fr-lungcancerregister-uppmrksammas-26052013.html 2016-05-17T11:01:33.541Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/Medimmune-AstraZenecas-Biologics-03042013.html 2016-05-17T11:00:40.575Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-outlines-strategy-21032013.html 2016-05-17T10:59:47.809Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/US-District-Court-rules-one-PULMICORT-RESPULES-02042013.html 2016-05-17T10:58:56.282Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-karolinska-institutet-translationell-forskning-21032013.html 2016-05-17T10:58:06.138Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-och-moderna-therapeutics-tecknar-avtal-21032013.html 2016-05-17T10:53:39.777Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/Bristol-Myers-Squibb-och-AstraZeneca-tar-01042013.html 2016-05-17T10:52:31.585Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/AstraZeneca-publicerar-arsredovisningen-25032013.html 2016-05-17T10:51:25.216Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/pathos-visar-behandlingsresultat-i-kolvrd-19032013.html 2016-05-17T10:50:48.648Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-etablerar-strategiska-fou-centra-18032013.html 2016-05-17T10:49:46.652Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/AstraZeneca-settles-litigation-over-CRESTOR-patent-25032013.html 2016-05-17T10:48:20.625Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/australia-federal-court-holds-crestor-patents-invalid-05032013.html 2016-05-17T10:47:28.546Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/AstraZeneca-appoints-Marc-Dunoyer-as-21032013.html 2016-05-17T13:00:59.467Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-meddelar-resultat-frn-en-lngtidsstudie-26022013.html 2016-05-17T10:44:35.606Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/bokslutsrapport-helr-31012013.html 2016-05-17T10:43:33.168Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-bidrar-till-ny-science-park-i-sdertlje-25012013.html 2016-05-17T10:42:51.617Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2013/astrazeneca-meddelar-ndringar-i-koncernledningen-15012013.html 2016-05-17T10:41:35.666Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018.html 2018-01-10T15:36:24.120Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/fasenra-receives-eu-approval-for-severe--eosinophilic-asthma.html 2018-01-10T15:41:24.883Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/lynparza-approved-by-us-fda-in-germline-brca-mutated-metastatic-.html 2018-01-15T09:04:37.378Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/risk-of-repeat-heart-attack-twice-as-likely-from-occlusions-in-a.html 2018-01-16T15:51:23.667Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/fasenra-receives-approval-in-japan.html 2018-01-19T07:55:42.637Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/lynparza-receives-approval-in-japan-for-the-treatment-of-advance.html 2018-01-19T07:59:24.170Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-listed-as-one-of-the-worlds-top-100-most-sustainable-companies-and-recognised-for-its-three-fold-increase-in-renewable-energy-usage-23012018.html 2018-01-23T07:21:30.046Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-reports-top-line-phase-iii-kronos-trial-results-for-.html 2018-01-27T08:58:26.873Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-plc-s-resultatrapport-foer-helaret-och-fjaerde-kvart.html 2018-02-02T07:00:17.087Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/brilinta-significantly-reduces-cv-events-and-coronary-death-beyo.html 2018-02-07T06:37:38.255Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/selumetinib-granted-orphan-drug-designation-by-the-us-fda-for-ne.html 2018-02-15T06:58:33.713Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/us-fda-approves-imfinzi-for-unresectable-stage-iii-non-small-cel.html 2018-02-17T07:18:58.343Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/lynparza-receives-positive-eu-chmp-opinion-in-platinum-sensitive.html 2018-02-26T09:39:19.745Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/medimmune-to-create-stand-alone-company-for--early-stage-inflamm.html 2018-02-28T07:08:59.537Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/the-european-medicines-agency-accepts-regulatory-submission-for-forxiga-in-adults-with-type-1-diabetes.html 2018-03-05T16:55:58.971Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-aims-to-advance-clinical-practice-in-cv-risk-management-with-new-data-at-acc-2018.html 2018-03-05T16:56:35.833Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/new-data-from-landmark-cvd-real-study-of-patients-with-type-2-di.html 2018-03-11T20:37:40.043Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-provides-update-on-mystic-trial-timeline.html 2018-03-12T06:32:44.159Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/michelle-werner-ny-marknadsbolagschef-for-astrazeneca-nordic-baltic.html 2018-03-14T13:40:50.477Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/lokelma-approved-in-the-eu-for-the-treatment-of-adults-with-hyperkalaemia.html 2018-03-22T17:21:21.045Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/us-fda-accepts-biologics-license-application-for-moxetumomab-pas.html 2018-04-03T05:51:13.778Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/the-european-medicines-agency-accepts-regulatory-submission-for-.html 2018-04-03T05:51:41.628Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca_s-early-and-late-stage-oncology-portfolio-showcased-.html 2018-04-04T11:00:23.999Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/1st-line-tagrisso-demonstrates-sustained-benefit-post-progressio.html 2018-04-13T14:58:43.562Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/updated-overall-survival-data-for-lynparza-in-brca-mutated-her2-.html 2018-04-16T05:27:44.850Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/us-fda-approves-tagrisso-as-1st-line-treatment-for-egfr-mutated-.html 2018-04-19T06:01:27.439Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-reports-results-from-the-arctic-trial-in-third-line-.html 2018-04-24T05:34:31.617Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/ny-studie--patienter-med-svar-astma-traeffar-saellan-en-laekare-.html 2018-04-27T08:22:19.903Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/tagrisso-receives-positive-eu-chmp-opinion-for-1st-line-treatmen.html 2018-04-27T11:25:22.425Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-and-luye-pharma-group-enter-agreement-for-rights-to-.html 2018-05-07T13:18:11.384Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/lynparza-tablets-receive-eu-approval-for-the-treatment-of-platinum-sensitive-relapsed-ovarian-cancer.html 2018-05-08T12:40:42.615Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-provides-update-on-galathea-phase-iii-trial-for-fase.html 2018-05-11T06:21:31.794Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-is-advancing-clinical-practice-in-respiratory-medici.html 2018-05-16T05:46:37.187Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/new-england-journal-of-medicine-publishes-two-trials-for-symbico.html 2018-05-17T15:27:26.217Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-plc-s-resultatrapport-foer-foersta-kvartalet-2018.html 2018-05-18T06:04:00.370Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/lokelma-approved-in-the-us-for-the-treatment-of-adults-with-hype.html 2018-05-18T21:46:26.673Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/regulatory-submission-in-japan-for-forxiga-in-type-1-diabetes.html 2018-05-21T05:33:24.806Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-heads-to-2018-asco-annual-meeting-with-its-diversifi.html 2018-05-24T05:29:30.771Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/imfinzi-significantly-improves-overall-survival-in-the-phase-iii.html 2018-05-25T05:18:00.347Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/update-on-terranova-phase-iii-trial-for-fasenra-in-chronic-obstr.html 2018-05-30T06:05:16.502Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/moxetumomab-pasudotox-pivotal-data-in-patients-with-previously-t.html 2018-06-04T10:12:55.631Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/lynparza-in-combination-with-abiraterone-delayed-disease-progres.html 2018-06-05T05:13:33.096Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/the-eu-approves-tagrisso-for-1st-line-treatment-of-egfr-mutated-.html 2018-06-09T06:26:37.681Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheime.html 2018-06-12T05:10:09.297Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-to-share-latest-data-from-an-industry-leading-portfo.html 2018-06-19T05:38:28Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/lynparza-significantly-delays-disease-progression-in-phase-iii--.html 2018-06-27T05:52:53.469Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/bydureon-receives-positive-eu-chmp-opinion-for-new-bcise-device-.html 2018-06-29T14:23:57.350Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/imfinzi-approved-in-japan-for-unresectable-stage-iii-non-small-c.html 2018-07-02T05:59:35.955Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/lynparza-approved-in-japan-for-brca-mutated-metastatic-breast-ca.html 2018-07-02T06:08:00.435Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/katarina-ageborg-ny-vd-for-astrazeneca-i-sverige.html 2018-07-16T13:22:56.320Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/atacand-to-be-divested-to-cheplapharm-in-europe.html 2018-07-24T06:18:10.903Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-plc-s-resultatrapport-foer-foersta-halvaret-och-andr.html 2018-07-26T06:03:19.758Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/imfinzi-receives-positive-eu-chmp-opinion-for-locally--advanced-.html 2018-07-27T13:09:45.445Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/selumetinib-granted-orphan-designation--in-europe-for-neurofibro.html 2018-08-03T06:19:18.440Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-is-advancing-understanding-of-cardio-renal-metabolic.html 2018-08-20T05:31:14.596Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/tagrisso-approved-in-japan-for-1st-line-treatment-of-egfr-mutate.html 2018-08-21T05:58:15.051Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-provides-update-on-aeristo-phase-iiib-trial-for--bev.html 2018-08-23T05:28:09.561Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/european-commission-approves-new-easy-to-use--once-weekly-bydure.html 2018-08-30T05:22:14.911Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lu.html 2018-08-31T05:29:39.617Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/tezepelumab-granted-breakthrough-therapy-designation-by-us-fda.html 2018-09-07T05:40:00.559Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-to-present-fasenra-long-term-safety-and-efficacy-dat.html 2018-09-13T05:51:55.610Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/us-fda-approves-lumoxiti-moxetumomab-pasudotox-tdfk-for-certain-patients-with-relapsed-or-refractory-hairy-cell-leukaemia.html 2018-09-14T06:28:14.210Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/the-lancet-respiratory-medicine-publishes-first-phase-iii-trial-.html 2018-09-16T15:49:37.416Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/fasenra-shows-consistent-safety-and-sustained-efficacy-in--long-.html 2018-09-18T05:45:45.152Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-presents-further-data-showing-the-interconnectivity-.html 2018-09-20T10:40:37.021Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/forxiga-uppnadde-ett-positivt-resultat-i-fas-iii-studien-declare.html 2018-09-24T05:35:50.193Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/european-commission-approves-imfinzi-for-locally-advanced--unres.html 2018-09-24T15:10:09.562Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/bydureon-receives-positive-eu-chmp-opinion-for-exscel-cardiovasc.html 2018-09-25T06:12:55.971Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/imfinzi-is-the-first-immunotherapy-to-demonstrate-significant-ov.html 2018-09-25T12:32:39.460Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/christina-malmberg-haegerstrand-ny-presschef-foer-astrazeneca-i-.html 2018-10-05T07:39:34.349Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-presents-advances-in-improving-treatment-options-for.html 2018-10-09T14:25:12.396Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/us-fda-grants-lynparza-orphan-drug-designation-for-pancreatic-ca.html 2018-10-16T05:49:06.796Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/chmp-issues-a-positive-opinion-for-bevespi-aerosphere--for-the-t.html 2018-10-19T12:33:49.020Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/new-data-on-mechanisms-of-acquired-resistance-after-1st-line-tag.html 2018-10-19T13:49:34.681Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/solo-1-phase-iii-trial-demonstrates-lynparza-maintenance-therapy.html 2018-10-22T05:52:01.884Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-to-present-new-data-demonstrating-breadth-of-researc.html 2018-10-22T06:17:00.566Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-strengthens-and-expands-oncology-development-and-com.html 2018-10-23T06:22:37.748Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/phase-iii-harmonize-global-trial-of-lokelma-confirms-efficacy-in.html 2018-10-25T16:06:43.949Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/agreement-with-gruenenthal-for-rights-to-nexium-in-europe-and-vi.html 2018-10-30T07:06:51.066Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/the-landmark-declare-timi-58-cardiovascular-outcomes-trial-of-fa.html 2018-11-01T07:00:28.975Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/divestment-of-rights-to-alvesco--omnaris-and-zetonna-to-covis-ph.html 2018-11-06T06:38:47.193Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-plc-s-resultatrapport-foer-de-foersta-nio-manaderna-.html 2018-11-08T07:10:37.487Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/farxiga-significantly-reduced-hospitalisation-for-heart-failure-.html 2018-11-10T21:35:29.791Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/us-fda-accepts-regulatory-submission-for-lynparza-maintenance-th.html 2018-11-12T07:03:46.002Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/fas-iii-studien-declare-timi-58-visar-att-dapagliflozin--forxiga.html 2018-11-12T14:10:32.825Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-to-divest-us-synagis-rights-to-sobi.html 2018-11-13T06:43:15.897Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-provides-update-on-the-phase-iii-mystic-trial-of--im.html 2018-11-16T06:48:12.031Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/us-fda-grants-fasenra-orphan-drug-designation-for-eosinophilic-g.html 2018-11-26T06:20:42.526Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-presents-clinical-research-advances-for-blood-cancer.html 2018-11-27T07:15:14.858Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/update-on-the-phase-iii-eagle-trial-of-imfinzi-and-tremelimumab-.html 2018-12-07T06:47:44.637Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/astrazeneca-and-cancer-research-uk-launch-functional-genomics-ce.html 2018-12-10T13:31:47.475Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/roxadustat-approved-in-china-for-the-treatment-of-anaemia-in-chr.html 2018-12-18T09:34:41.504Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/lynparza-approved-by-us-fda-for-1st-line-maintenance-therapy-in-.html 2018-12-19T18:58:50.564Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2018/phase-iii-olympus-and-rockies-trials-for-roxadustat-met-their-pr.html 2018-12-20T06:35:49.638Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021.html 2021-01-04T07:17:42.368Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/atacand-divestment-to-cheplapharm-in-more-than-70-countries-comp.html 2021-01-04T07:20:00.792Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/farxiga-granted-priority-review-in-the-us--for-the-treatment-of-.html 2021-01-06T07:29:09.595Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/serum-institute-of-india-obtains-emergency-use-authorisation-in-.html 2021-01-06T13:26:05.232Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-to-showcase-transformative-data-across-diverse-pipel.html 2021-01-15T06:56:39.579Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/imfinzi-approved-in-the-eu-for-less-frequent--fixed--dose-use-in.html 2021-01-15T07:36:43.370Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/enhertu-approved-in-the-us-for-the-treatment-of-patients-with-pr.html 2021-01-18T07:33:14.359Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/enhertu-approved-in-the-eu-for-the-treatment-of-her2-positive-me.html 2021-01-20T07:29:47.235Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/calquence-met-primary-efficacy-endpoint-in-head-to-head-trial-ag.html 2021-01-25T07:30:01.946Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/calquence-approved-in-japan-for-the-treatment-of--relapsed-or-re.html 2021-01-25T07:34:03.554Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-r.html 2021-01-26T07:11:33.580Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/-datopotamab-deruxtecan-and-enhertu-show-promising-early--clinic.html 2021-01-29T07:38:46.245Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/tagrisso-extended-disease-free-survival-regardless-of-prior-adju.html 2021-01-29T09:38:05.377Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/covid-19-vaccine-astrazeneca-recommended-for-use-in-the-eu.html 2021-01-29T15:59:40.864Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/covid-19-vaccine-astrazeneca-authorised-for-use-in-the-eu.html 2021-01-29T21:15:23.312Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-agrees-to-divest-viela-shareholding.html 2021-02-01T12:12:50.693Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/covid-19-vaccine-astrazeneca-confirms-100--protection-against-se.html 2021-02-03T07:35:43.837Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/-forxiga-approved-in-china-for-heart-failure.html 2021-02-04T07:30:31.988Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/update-on-kestrel-phase-iii-trial-of-imfinzi-with-or-without-tre.html 2021-02-05T07:28:14.194Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/divestment-of-crestor-in-europe-to-gruenenthal-completed.html 2021-02-10T07:30:29.177Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-and-idt-biologika-sign-letter-of-intent-to-increase-.html 2021-02-10T14:07:50.084Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-plc-s-resultatrapport-foer-det-fjaerde-kvartalet-och.html 2021-02-11T07:21:31.372Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-covid-19-vaccine-authorised--for-emergency-use-by-th.html 2021-02-15T20:32:47.125Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/idmc-has-concluded-that-olympia-trial-of-lynparza-crossed-superi.html 2021-02-17T07:19:15.577Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/-voluntary-withdrawal-of-imfinzi-indication-in-advanced-bladder-.html 2021-02-22T07:22:53.875Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/tezepelumab-is-the-first-biologic-to-consistently-and-significan.html 2021-02-26T14:28:50.627Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/further-update-on-us-regulatory-review-of-roxadustat-in-anaemia-.html 2021-03-01T21:33:16.090Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-advances-mass-global-rollout-of-covid-19-vaccine--th.html 2021-03-02T12:58:59.398Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/us-court-decision-favours-symbicort-in-patent-litigation.html 2021-03-03T07:17:20.638Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/update-on-the-safety-of-covid-19-vaccine-astrazeneca.html 2021-03-23T08:08:30.228Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/divestment-of-viela-shareholding-completed.html 2021-03-23T08:09:16.740Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-to-supply-the-us-with-up-to-half-a-million-additiona.html 2021-03-23T08:10:38.076Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/uk-and-eu-regulatory-agencies-confirm-covid-19-vaccine-astrazene.html 2021-03-23T08:11:15.542Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/azd1222-us-phase-iii-trial-met-primary-efficacy--endpoint-in-pre.html 2021-03-23T08:12:37.454Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/statement-on-the-passing-of-jose-baselga-.html 2021-03-23T08:13:15.945Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/update-following-statement-by-niaid-on-azd1222-us-phase-iii-tria.html 2021-03-24T08:33:14.710Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-effica.html 2021-03-25T05:44:55.381Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-accelerates-early-oncology-pipeline-across-key-strat.html 2021-04-09T05:44:19.332Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/update-on-the-dare-19-phase-iii-trial-for-farxiga-in-covid-19.html 2021-04-12T05:24:41.320Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/publication-of-circular-and-notice-of-astrazeneca-general-meetin.html 2021-04-12T12:01:38.005Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/tagrisso-approved-in-china-for-the-adjuvant-treatment-of-patient.html 2021-04-14T05:08:35.989Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-receives-us-clearance-of-proposed-acquisition-of-ale.html 2021-04-16T10:38:43.864Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/nirsevimab-melody-phase-iii-trial-met-primary-endpoint-of-reduci.html 2021-04-26T05:50:15.954Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/tagrisso-recommended-for-approval-in-the-eu-by-chmp-for-the-adju.html 2021-04-26T05:54:54.080Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/selumetinib-recommended-for-approval-in-the-eu-by-chmp-as-the-fi.html 2021-04-26T06:00:52.264Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-plc-s-resultatrapport-foer-foersta-kvartalet-2021.html 2021-04-30T05:24:05.907Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/farxiga-approved-in-the-us-for-the-treatment-of-chronic-kidney-d.html 2021-05-01T04:51:44.472Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/imfinzi-and-tremelimumab-with-chemotherapy-demonstrated-overall-.html 2021-05-07T05:21:05.446Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-shareholders-vote-in-favour-of-proposed-acquisition-.html 2021-05-11T13:43:46.622Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/results-of-annual-general-meeting-held-on-11-may-2021.html 2021-05-11T13:47:53.272Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-asco-2021-data-support-ambition-to-revolutionise-can.html 2021-05-19T20:38:54.718Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-covid-19-vaccine-vaxzevria-authorised-for-emergency-.html 2021-05-21T05:43:32.210Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/tagrisso-approved-in-the-eu-for-the-adjuvant-treatment-of-patien.html 2021-05-28T05:25:26.042Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/anifrolumab-showed-benefit-across-different-measures-of-skin-and.html 2021-06-02T05:41:09.504Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/lynparza-reduced-the-risk-of-cancer-recurrence-by-42--in-the-adj.html 2021-06-03T20:50:38.638Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-appoints-aradhana-sarin-as-new-chief-financial-offic.html 2021-06-04T05:44:44.407Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/imfinzi-demonstrated-unprecedented-survival-in-unresectable---st.html 2021-06-04T05:48:03.789Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/calquence-demonstrated-fewer-incidences-of-atrial-fibrillation-v.html 2021-06-07T05:52:26.240Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/covid-19-vaccine-astrazeneca-effective-against-delta---indian---.html 2021-06-17T13:16:25.841Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/update-on-azd7442-storm-chaser-trial--in-post-exposure-preventio.html 2021-06-15T05:24:46.818Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-welcomes-court-ruling--on-supply-of-its-covid-19-vac.html 2021-06-18T12:11:58.357Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/koselugo-approved-in-the-eu-for-children-with-neurofibromatosis-.html 2021-06-22T05:14:52.337Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/orpathys-approved-in-china-for-patients--with-lung-cancer-and-me.html 2021-06-23T06:14:28.516Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/lynparza-approved-in-china-for-the-treatment-of-brca--mutated-me.html 2021-06-24T05:40:11.353Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/first-covid-19-variant-vaccine-azd2816-phase-ii-iii-trial--parti.html 2021-06-27T11:42:24.169Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/nirsevimab-medley-phase-ii-iii-trial-demonstrated-favourable-saf.html 2021-06-28T09:56:04.970Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/forxiga-recommended-for-approval-in-the-eu-by-chmp-for-the-treat.html 2021-06-28T10:04:26.248Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-appoints-dr--susan-galbraith-as-executive--vice-pres.html 2021-06-28T12:39:58.220Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/vaxzevria-induced-immunity-for-at-least-one-year-following-a-sin.html 2021-06-28T13:55:44.237Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-receives-clearance-from-the-european-commission-for-.html 2021-07-06T08:20:25.972Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/tezepelumab-regulatory-submission-accepted-and-granted-fda--prio.html 2021-07-08T07:37:24.719Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-receives-final-regulatory-clearance-for-the-proposed.html 2021-07-14T08:24:07.452Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/status-on-fda-advisory-committee-vote-on-roxadustat-in-anaemia-o.html 2021-07-16T09:46:02.891Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/imfinzi-approved-in-china-for-the-treatment-of-extensive-stage-s.html 2021-07-21T09:45:42.152Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/acquisition-of-alexion-completed.html 2021-07-21T13:40:07.497Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/vaxzevria-is-highly-effective-after-one-dose-against-severe-dise.html 2021-07-23T09:54:27.919Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/ultomiris-recommended-for-approval-in-the-eu-by-chmp-for-childre.html 2021-07-26T05:25:40.540Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/vaxzevria-showed-no-increased-incidence-of-thrombosis-with-throm.html 2021-07-28T05:36:26.226Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/vaxzevria-and-mrna-covid-19-vaccines-showed-similar-and-favourab.html 2021-07-28T05:39:31.401Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-plc-s-resultatrapport-foer-foersta-halvaret-2021.html 2021-07-29T06:05:58.354Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/saphnelo--anifrolumab--approved-in-the-us-for-moderate-to-severe.html 2021-08-02T06:55:46.600Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/enhertu-significantly-improved-progression-free-survival-in-dest.html 2021-08-09T09:37:48.861Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/forxiga-approved-in-the-eu-for-the-treatment-of-chronic-kidney-d.html 2021-08-09T10:13:39.296Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/update-on-us-regulatory-review-of-roxadustat--in-anaemia-of-chro.html 2021-08-12T06:15:50.579Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/-azd7442-provent-phase-iii-prophylaxis-trial-met-primary-endpoin.html 2021-08-20T05:41:38.753Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/-update-on-champion-als-phase-iii-trial-of-ultomiris-in-amyotrop.html 2021-08-20T05:45:19.502Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/alxn1840-focus-phase-iii-trial-in-wilson-disease-met-primary-end.html 2021-08-26T05:26:44.737Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/-forxiga-approved-in-japan-for-the-treatment-of-chronic-kidney-d.html 2021-08-26T05:29:44.587Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-lung-and-breast-cancer-data-at-wclc-and-esmo-2021--u.html 2021-09-02T05:47:21.685Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/ultomiris-approved-in-the-eu-for-children-and-adolescents-with-p.html 2021-09-03T05:44:18.051Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-and-european-commission-reach-settlement-agreement--.html 2021-09-03T07:38:03.480Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/fixed-dose-combination-of-albuterol-and-budesonide--pt027--demon.html 2021-09-09T05:36:44.643Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/imfinzi-and-tremelimumab-with-chemotherapy-improved-progression-.html 2021-09-09T14:32:09.573Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/imfinzi-combined-with-novel-immunotherapies-improved-clinical-ou.html 2021-09-17T11:25:42.527Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/enhertu-demonstrated-clinically-meaningful-and-durable-response-.html 2021-09-17T15:04:45.696Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/enhertu-demonstrated-robust-and-durable-tumour-response-of-54-9-.html 2021-09-18T11:18:21.752Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/enhertu-reduced-the-risk-of-disease-progression-or-death-by-72--.html 2021-09-18T12:37:33.131Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/imfinzi-plus-chemotherapy-tripled-patient-survival-at-three-year.html 2021-09-18T15:27:32.689Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-to-invest--360m-in-advanced-manufacturing-facility-i.html 2021-09-21T05:35:23.674Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-to-discover-and-develop-self-amplifying-rna-therapeu.html 2021-09-23T05:36:34.854Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/lynparza-in-combination-with-abiraterone-significantly-delayed-d.html 2021-09-24T05:36:29.678Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/saphnelo-approved-in-japan-for-systemic-lupus-erythematosus.html 2021-09-28T05:26:43.147Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-to-fully-acquire-caelum-biosciences.html 2021-09-29T05:30:27.892Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/enhertu-granted-breakthrough-therapy-designation-in-us-for-patie.html 2021-10-04T05:39:21.857Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/azd7442-request-for-emergency-use-authorization--for-covid-19-pr.html 2021-10-05T05:35:02.906Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/tezepelumab-granted-orphan-drug-designation-in-the-us--for-eosin.html 2021-10-08T10:25:06.097Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/azd7442-reduced-risk-of-developing-severe-covid-19-or-death--in-.html 2021-10-11T05:39:20.714Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/imfinzi-plus-tremelimumab-significantly-improved-overall-surviva.html 2021-10-15T05:30:21.184Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/imfinzi-plus-chemotherapy-significantly-improved-overall-surviva.html 2021-10-25T06:04:42.626Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-to-transfer-global-rights-for-eklira-and-duaklir-to-.html 2021-11-01T06:29:08.227Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-advances-ambition-to-redefine-care-for-blood-cancer-.html 2021-11-05T06:40:53.130Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-plc-s-resultatrapport-foer-de-foersta-nio-manaderna-.html 2021-11-12T06:34:12.206Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/two-billion-doses-of-astrazeneca-s-covid-19-vaccine-supplied-to-.html 2021-11-16T06:37:44.317Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-ri.html 2021-11-18T07:35:50.081Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-unveils-the-discovery-centre--disc--in-cambridge.html 2021-11-23T07:27:37.768Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/lynparza-granted-priority-review-in-the-us-for--brca-mutated-her.html 2021-11-30T06:41:33.305Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-reinforces-leadership-in-breast-cancer-at-sabcs-2021.html 2021-12-03T07:28:38.211Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-and-ionis-sign-deal-to-develop-and-commercialise-epl.html 2021-12-07T06:34:55.286Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/evusheld--formerly-azd7442--long-acting-antibody-combination--au.html 2021-12-08T21:15:01.719Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/enhertu-additional-analyses-further-reinforce-ground-breaking-ef.html 2021-12-09T14:55:10.551Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazenecas-nya-covid-laekemedel-tillverkas-i-sverige.html 2021-12-10T06:58:19.246Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/calquence-reduced-the-risk-of-disease-progression-or-death-by-71.html 2021-12-12T14:43:51.239Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/evusheld-long-acting-antibody-combination-retains-neutralising-a.html 2021-12-16T13:54:16.247Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/tezspire--tezepelumab--approved-in-the-us-for-severe-asthma-.html 2021-12-17T21:30:01.922Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazenecas-fabrik-foer-framtidens-biologiska-laekemedel-skapar.html 2021-12-20T06:27:40.251Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/saphnelo-recommended-for-approval-in-the-eu-by-chmp-for-the-trea.html 2021-12-20T06:31:40.740Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/ultomiris-accepted-for-fda-priority-review-for-gmg.html 2021-12-21T07:24:51.913Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/evusheld-long-acting-antibody-combination-retains-neutralising-a0.html 2021-12-23T06:31:49.095Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/vaxzevria-significantly-boosted-antibody-levels-against-omicron.html 2021-12-23T06:59:43.744Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/astrazeneca-and-ionis-close-agreement-to-develop-and-commerciali.html 2021-12-29T07:20:27.614Z https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/transfer-of-global-rights-for-eklira-and-duaklir-to-covis-pharma.html 2022-01-05T07:25:12.316Z https://www.astrazeneca.se/media/Bildbank.html 2025-12-08T13:17:06.226Z https://www.astrazeneca.se/media/podcast.html 2026-07-15T11:04:57.701Z https://www.astrazeneca.se/aktuellt.html 2024-06-11T14:00:17.283Z https://www.astrazeneca.se/kontakta-oss.html 2025-09-01T07:00:01.248Z https://www.astrazeneca.se/information-om-cookies.html 2018-03-02T09:12:01.202Z